Walgreens said it is making significant strides to increase on-site testing capacity at more than 5,000 Walgreens pharmacy locations by April 1, with more than half of sites located in socially vulnerable areas.
This kit will be Walgreens first over-the-counter COVID-19 testing option available for purchase in-store and is aimed to address stores that do not currently have testing available on-site.
This builds upon Walgreens and Labcorp's recent announcement of Pixel by Labcorp COVID-19 PCR Test Home Collection Kit availability on Walgreens Find Care, a digital health platform available on the Walgreens app and Walgreens.com.
The addition of this over-the-counter collection kit in-store will help to ensure customers have access to testing solutions when and how they need it at-home, in-store or at one of Walgreens' other conveniently located testing sites.
Customers will be able to purchase the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit at the pharmacy counter without a prescription at up to 6,000 Walgreens stores nationwide.
Once purchased, customers can self-administer the test collection using a short nasal swab and send their sample back to Labcorp via pre-paid FedEx Express Overnight. Once processed by Labcorp, test results are accessed by the customer via the Pixel by Labcorp website.
If a COVID-19 test is positive, a Labcorp-verified healthcare staff member will contact individuals directly by phone or mail to discuss next steps. Pixel by Labcorp has contracted with a physician network to provide independent physician services for consultation.
The Pixel by Labcorp COVID-19 PCR Test Home Collection Kit is not a substitute for visits to a healthcare professional and is for use by adults 18 and older.
Labcorp's COVID-19 PCR test has not been FDA cleared or approved and has been authorized by the FDA under an emergency use authorization only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21 USC. § 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner. Ltd. quantities available per store.
Walgreens is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).
The company operates more than 9,000 retail locations across America, Puerto Rico and the US Virgin Islands.
Labcorp is a global life sciences company that provides diagnostics and drug development capabilities.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval